“…The main clinical, imaging, and laboratory findings of P102L mutations described in the literature are summarized in Table 2. Cognitive decline is typically present, but is usually mild and occurs later in the evolution of the disease (Cagnoli et al, 2008;Kovács et al, 2002;Park et al, 2010;Takazawa et al, 2010;Young, Clark, Piccardo, Dlouhy, & Ghetti, 1997); although, GSS P120L cases with cognitive decline, as one of the prominent symptoms, have been reported (Barbanti et al, 1996;Chi et al, 2010; Downloaded by [Florida Atlantic University] at 20:04 17 November 2014 Giovagnoli et al, 2008;Majtényi et al, 2000;Park et al, 2010;Webb et al, 2008). Cognitive decline, if present, often develops late in the course of the disease, seldom manifests as prominent dementia and is usually not accompanied by behavioral and psychiatric symptoms such as paranoia, delusions, and severe anosognosia.…”